Pharmaceuticals News 30 November 2025

Johnson & Johnson (JNJ) Stock Near Record Highs: New EU Drug Approval, Oncology Deal and 2026 Outlook

As of December 2, 2025, Johnson & Johnson (NYSE: JNJ) is trading just below all‑time highs, supported by a powerful 2025 rally, a fresh European Union drug approval, a new $3.05 billion oncology acquisition, and a planned spin‑off of its

2 December 2025

Eli Lilly (LLY) Stock on December 2, 2025: Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025. Eli Lilly Stock

2 December 2025

Business News · Healthcare · Investing · NYSE:LLY · Pharmaceuticals · Stock Market

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc (LSE: GSK, NYSE: GSK) heads into the final month of 2025 near multi‑year highs, powered by a strong run of earnings beats, a revived oncology franchise and a looming change at the top of the company. As of

2 December 2025

CEO News · Earnings Reports · Investor Updates · NYSE:GSK · Pharmaceuticals · Stock Market

Bayer Stock Rockets on U.S. Roundup Breakthrough – Is the 13% Rally the Start of a Trend?

Bayer’s share price is exploding today. On 2 December 2025, the German blue chip (ISIN DE000BAY0017, ticker BAYN) is trading around €34–35 on Xetra, up roughly 13% intraday and at a fresh year high. FinanzNachrichten.de+1 The trigger: a major twist in the U.S. Roundup™ glyphosate litigation –

2 December 2025

Financial Analysis · Investment Trends · Legal News · NYSE:BAYRY · Pharmaceuticals · Stock Market

Wockhardt share price soars 27% in two days after historic US FDA step for Zaynich

Wockhardt Limited has suddenly jumped back into the market spotlight. On 2 December 2025, the Wockhardt share price extended a powerful breakout rally triggered by a landmark US regulatory milestone for its novel antibiotic Zaynich, making the stock one of

2 December 2025

Financial Updates · Investment News · Pharmaceuticals · Stock Market · US FDA

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie Inc. (NYSE: ABBV) heads into December 2025 as one of the world’s largest healthcare companies, with new migraine data, fresh oncology approvals, a raised 2025 profit forecast and looming U.S. drug‑pricing reforms all shaping sentiment around the stock. The

1 December 2025

Earnings Reports · Healthcare Innovation · Investment Analysis · Pharmaceuticals · Stock Market

GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now

GSK plc (NYSE: GSK) heads into December 2025 as one of the stronger-performing big pharma names, with the share price hovering just below a 52‑week high after a year of earnings beats, upgraded guidance, revived cancer assets and a looming

1 December 2025

CEO Updates · Company News · Investment Tips · NYSE:GSK · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock Outlook Before the December 1, 2025 Open: Price, Metsera Obesity Deal, Dividend Payout and Wall Street Forecasts

As U.S. markets prepare to reopen on Monday, December 1, 2025, Pfizer Inc. (NYSE: PFE) heads into the new week trading in a tight range but surrounded by a flurry of fresh analysis, institutional activity and strategic news from November

30 November 2025

Dividend Stocks · Financial Analysis · Investing · NYSE:PFE · Pharmaceuticals · Stock Market

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie Inc. (NYSE: ABBV) heads into Monday’s December 1, 2025 open sitting near the middle of its recent trading range, with a lot of fresh information for investors to digest from November 28–30. As of the latest close on November

30 November 2025

Healthcare · Investment · Market Analysis · NYSE:ABBV · Pharmaceuticals · Stocks

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Published: November 30, 2025 Eli Lilly and Company (NYSE: LLY) heads into Monday’s session after one of the most consequential months in its history: a brief stint above a $1 trillion market value, a huge November rally powered by obesity

30 November 2025

Financial News · Investing · Market Analysis · NYSE:LLY · Pharmaceuticals · Stock Market

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 with its share price near the top of its 52‑week range, a richer pipeline, and a wave of new research coverage and corporate news that investors are

30 November 2025

Analyst Ratings · Dividend Analysis · Investment News · NYSE:MRK · Pharmaceuticals · Stock Market

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly and Company (NYSE: LLY) has just wrapped up one of the most dramatic months in its history. The drugmaker’s shares have surged in November, pushing the company past a $1 trillion market value and cementing its role as

30 November 2025

Company Analysis · Financial News · Investing · Pharmaceuticals · Stock Market

Pharmaceuticals News 30 November 2025 - 2 December 2025